← All trials
NCT04768231
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2021
- Primary completion
- Dec 31, 2022
- Completion date
- Dec 31, 2023
- First posted
- Feb 24, 2021
- Last posted
- Feb 24, 2021
- Enrollment
- 130
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Universidad Autonoma de BarcelonaLead sponsor
- Radboud UniversityCollaborator
- University of GroningenCollaborator
- Universidad Autonoma de BarcelonaOverall official - principal investigator
- University Hospital Center of Sao Joao (UHCSJ)Collaborator
- Instituto Nacional de Enfermedades Respiratorias y del Ambiente, ParaguayCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.